Share-Based Compensation Plans (Tables)

9 Months Ended

Sep. 30, 2025

Share-Based Payment Arrangement, Noncash Expense [Abstract]

A summary of option activity for the nine months ended September 30, 2025 is presented below:


	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2024		5,242,916		$	28.76
Granted		598,432			3.22
Exercised		—			—
Forfeited		(220,891	)		12.34
Expired		(478,522	)		42.76
Outstanding at September 30, 2025		5,141,935		$	25.26		7.63	$	2,426,379
Vested or expected to vest at September 30, 2025		5,141,935		$	25.26		7.63	$	2,426,379
Exercisable at September 30, 2025		2,670,148		$	43.70		6.34	$	211,341

Summary of Non-vested Stock Activity

A summary of non-vested stock activity for the nine months ended September 30, 2025 is presented below:


	Non-vested Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2024		42,222		$	17.30
Granted		1,604,656			4.30
Vested		(1,545,018	)		4.38
Forfeited		(10,635	)		21.68
Outstanding at September 30, 2025		91,225		$	7.00

Schedule of Share-Based Compensation Expense

The impact on our results of operations from share-based compensation for the three and nine months ended September 30, 2025 and 2024, was as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Research and development	$	771	$	4,649	$	2,374	$	10,685
General and administrative		2,037		4,631		7,208		12,081
Total share-based compensation expense	$	2,808	$	9,280	$	9,582	$	22,766

AGENUS INC 10-Q